Aurobindo Pharma has received approval for the issue of equity shares through qualified institutions placement up to $350 million. The board at its meeting held on December 10, 2014 has approved for the same. At the aforesaid meeting, it has also been decided to hold a general meeting of the members of the Company for the above purpose on January 21, 2015.
Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1673.45 |
| Dr. Reddys Lab | 1235.10 |
| Cipla | 1233.00 |
| Zydus Lifesciences | 939.95 |
| Lupin | 2330.65 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: